Peter C. Enzinger

机构：Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center · ORCID：0009-0009-9831-1248

发表论文 303 篇 · 总被引 27651 次 · h-index 66

代表论文

• Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology (2025 · Journal of the National Comprehensive Cancer Network · 被引 205)
• Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma (2024 · New England Journal of Medicine · 被引 97)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 23)
• The 2025 American Association for Thoracic Surgery (AATS) expert consensus document: Surgical management of esophageal and gastroesophageal junction cancer (2025 · Journal of Thoracic and Cardiovascular Surgery · 被引 17)
• Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study (2025 · ESMO Open · 被引 15)
• Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study (2025 · ESMO Gastrointestinal Oncology · 被引 13)